|
Item
|
mean ± SD
|
Range
|
|---|
|
Number of cases
|
217
| |
|
Male, n(%)
|
120 (55.3 %)
| |
|
Age, year
|
67.15 ± 0.61
|
40-85
|
|
Disease duration, year
|
5.78 ± 4.32
|
1-23
|
|
H&Y stage
|
1.43 ± 0.55
|
1-4
|
|
Use of levodopa, n(%)
|
193 (88.9 %)
| |
|
Use of DA agonists, n(%)
|
101 (46.5 %)
| |
|
Levodopa, (mg/d)
|
494.94 ± 348.03
|
100-2825
|
|
DA agonist LED, (mg/d)
|
135.15 ± 66.8
|
50-300
|
|
TLED, (mg/d)
|
548.53 ± 382.12
|
50-3000
|
- Note:DA agonist-LED (DA-LED, mg/d) = piribedil (mg/d) × 1 + pramipexole (mg/d) × 100. Total LED (TLED, mg/d) = regular levodopa dose (mg/d) × 1 + levodopa CR dose (mg/d) × 0.75 + DA-LED, and plus [regular levodopa dose (mg/d) + CR levodopa dose(mg/d) × 0.75] × 0.33 if taking COMT-I [24]
